A team committed to the development of a therapeutic portfolio in hearing loss
WHO ARE WE ?
Sensorion is a pioneering biotech company, dedicated to the development of innovative therapies to restore, treat and prevent within the field of hearing loss
Over 30 years of leadership and operational experience across the biotechnology,
pharmaceutical, and medical device industries
Previously Senior Vice President, Strategy and Business Development at Alexion – AstraZeneca Rare Disease and President and CEO of LogicBio Therapeutics, which was acquired by Alexion in 2022.
Deep expertise in rare disease drug development and regenerative medicine with a strong track record of building scalable businesses and accelerating growth.
Louis J. Arcudi III
Chief Financial Officer
Seasoned biopharmaceutical executive with Chief Financial Officer and Chief Executive Officer experience at U.S.-listed and private biotechnology companies.
Previously Chief Financial Officer of Amolyt Pharma, which raised a $138 million Series C financing in 2023 and was acquired by AstraZeneca in 2024 for up to $1.05 billion, and Chief Executive Officer of Millendo Therapeutics, which he led through its merger with Tempest Therapeutics in 2021.
Deep expertise in financings, strategic transactions and financial leadership of transatlantic biotechnology companies, built on prior roles at Idera Pharmaceuticals, Peptimmune and Genzyme.
Bernd Schmidt
Chief Technical Officer
Over 20 years of leadership and operational experience across the biotechnology and pharmaceutical industries
Expertise spanning CMC strategy, product development, manufacturing, quality and global supply across advanced therapies, biologics and pharmaceuticals
Prior to joining Sensorion, served as SVP Product Delivery at Quell Therapeutics and held senior leadership roles within GSK’s global medicines development and supply organisation
Stéphanie Filipe
Head of Business Operations & Portfolio Management
20 years in therapeutic products development in Biotechs from bench to beside including gene and cell therapies
Formerly R&D Director at OTR3, Program Leader at Cellectis
Ph.D., Cellular Biology & Biochemistry
Laurent Désiré
Head of Preclinical Development
Over 20 years in pharmaceutical R&D and clinical development, especially in gene therapy and neuroscience
Formerly Head of Cellular and Molecular Biology unit at YposKesi, and R&D Executive Director at Diaxonhit and ExonHit
Ph.D., Biology of Aging
Amit Munshi
Chairman of the Board, Independent Director
35 years of experience in the healthcare industry
Previously served as CEO of Orna Therapeutics, ReNagade Therapeutics and Arena Therapeutics
Executive leadership having led multiple biotech companies to successful transformational growth milestones and exits
Occupied multiple roles in Big Pharma
Fred Chereau
CEO
Over 30 years of leadership and operational experience across the biotechnology,
pharmaceutical, and medical device industries
Previously Senior Vice President, Strategy and Business Development at Alexion – AstraZeneca Rare Disease and President and CEO of LogicBio Therapeutics, which was acquired by Alexion in 2022.
Deep expertise in rare disease drug development and regenerative medicine with a strong track record of building scalable businesses and accelerating growth.
Khalil Barrage
Director Representative of Invus
20 years of experience in portfolio management at The Olayan Group in New York
Managing Director for the Invus Group in New York and Board member of Protagenic and Celtaxsys
Julien Miara
Director, Representative of Invus
10 years of experience in investment, covering biotechnology among other sectors
Director at Invus
Cédric Moreau
Director representing Sofinnova Partners
18 years of experience in investment banking and in life sciences
Partner in the Crossover investment team at Sofinnova Partners
Eric de la Fortelle
Independent Director
10 years of experience as a scientific researcher in biotechnology, followed by CEO and board member roles
Head of Business Development and Strategy at IOB (Institute of Molecular and Clinical Ophthalmology Basel), since March 2025
Managing Partner at Cathay Health
Aniz Girach
Independent Director
M.D., over 25 years’ experience in the biotech and pharma industry
More than 20 years experience in Healthcare Innovation and Capital Investment
Former emergency physician in the UK’s National Health Service
MD., awarded with Distinction from Imperial College London and holds a BA(hons) in Physiology from the University of Oxford
Board Member of Sensome
Federico Mingozzi, Ph.D.
Independant Director
More than 25 years experience in gene therapy, immunology, as well as biochemistry and
molecular biology
CEO at Nava Therapeutics
Previously Chief Science and Technology at Spark Therapeutics
He holds a bachelor’s degree in biology and a Ph.D. in biochemistry and molecular biology from the
University of Ferrara in Italy, and a M.B.A. from Drexel University.
Pr Christine Petit
Chair of the Scientific Advisory Board
Chair of Genetics and Cellular Physiology, Professor at College de France and at Institut Pasteur (Paris)
Head of the Laboratory of Genetics and Physiology of Hearing at Institut Pasteur
Managing Director of the French Hearing Institute
Member of the French and American Sciences Academies and the American Medical Academy
Pr Alain Fischer
Professor at College de France
Former director and founding member of the Institute for Genetic Diseases (Imagine)
Former director of the pediatric immuno-hematology department at Necker Hospital
Dr Robert Dow
Chief Development Officer at Scendea, providing technical/regulatory advice and product development strategy
More than 37 years of experience in the pharmaceutical and biotech industry
Former Chief Medical Officer at PPD Inc.; prior executive roles at Syntex, Hoffmann-La Roche, and Cell Genesys
Substantial experience across toxicology, pharmacokinetics, clinical science, clinical operations, regulatory affairs, and drug safety, from pre-clinical through late-stage development
Pr Paul Avan
Physicist and Medical Doctor in Biophysics
Head of the Center for Research and Innovation in Human Audiology at Hearing Institute (Paris)
Designed original objective methods of exploration of the cochlea and auditory pathways
Dr. Diane Lazard
ENT Surgeon and former Head of Clinic at AP-HP
Principal Associate Investigator at the Hearing Institute (Paris)
Currently pursuing research on deciphering language processing variability in deafness
Dr. Hernán López-Schier
Research Director, Research Innovation, at New York University Abu Dhabi (since 2024); previously Research Director and Group Leader at Helmholtz Zentrum München (2012–2022)
Currently pursuing research on fundamental sensory biology and sensory dysfunction
His group was the first to visualize the regeneration of mechanosensory hair cells in their natural context
04 67 20 77 30
